Kalli C. Catcott

Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses

Naniye Malli Cetinbas, Travis Monnell, Jahna Soomer-James et al. · Nature Communications · 2024 · 55 citations · Full text

Discovery and Optimization of HKT288, a Cadherin-6–Targeting ADC for the Treatment of Ovarian and Renal Cancers

Carl Uli Bialucha, Scott D. Collins, Xiao Li et al. · Cancer Discovery · 2017 · 52 citations · Full text

Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates

Jeremy R. Duvall, Joshua D. Thomas, Raghida A. Bukhalid et al. · Journal of Medicinal Chemistry · 2023 · 44 citations · Full text

Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer

Dorin Toader, Shawn P. Fessler, Scott D. Collins et al. · Molecular Cancer Therapeutics · 2023 · 33 citations · Full text

Engineering, Immunology, Immunotherapeutics +19

Abstract 6706: Systemic administration of STING agonist antibody-drug conjugates elicit potent anti-tumor immune responses with minimal induction of circulating cytokines

Raghida A. Bukhalid, Jeremy R. Duvall, Naniye Mallı Cetinbas et al. · Cancer Research · 2020 · 25 citations

Minimal Induction, Immunology, Immunologic Mechanism +20